Incyte (MEX:INCY) Cyclically Adjusted FCF per Share: MXN41.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
83 GF Score
Price MXN2,067.00
GF Value MXN1,797.83
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Cyclically Adjusted FCF per Share?

Incyte MEX:INCY 83 Cyclically Adjusted FCF per Share is MXN41.13 as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 83/100 and a GF Value™ of MXN1,797.83 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Incyte's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN30.877. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN41.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Incyte's average Cyclically Adjusted FCF Growth Rate was 41.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 26.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 82.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Incyte was 175.20% per year. The lowest was -11.60% per year. And the median was 11.35% per year.

As of today (2026-07-15), Incyte's current stock price is MXN2067.00. Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN41.13. Incyte's Cyclically Adjusted Price-to-FCF of today is 50.26.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Incyte was 1631.50. The lowest was 36.22. And the median was 77.51.


Incyte  (MEX:INCY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Incyte's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2067.00/41.13
=50.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Incyte was 1631.50. The lowest was 36.22. And the median was 77.51.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Incyte Cyclically Adjusted FCF per Share Related Terms


Incyte Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Incyte's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Cyclically Adjusted FCF per Share Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.79 20.69 32.43 30.55 36.77

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.09 30.50 35.70 36.77 41.13

MEX:INCY vs INSM, BNTX, ROIV: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Incyte's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted Price-to-FCF falls into.


MEX:INCY
83GF Score
Incyte Corp MEX:INCY
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=30.877/330.2130*330.2130
=30.877

Current CPI (Mar. 2026) = 330.2130.

Incyte Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -6.194 241.018 -8.486
201609 7.827 241.428 10.705
201612 8.290 241.432 11.338
201703 -18.766 243.801 -25.417
201706 7.604 244.955 10.251
201709 1.606 246.819 2.149
201712 -10.653 246.524 -14.269
201803 0.708 249.554 0.937
201806 1.974 251.989 2.587
201809 15.099 252.439 19.751
201812 5.323 251.233 6.996
201903 12.279 254.202 15.951
201906 9.333 256.143 12.032
201909 26.036 256.759 33.484
201912 8.832 256.974 11.349
202003 -78.190 258.115 -100.030
202006 23.615 257.797 30.249
202009 13.055 260.280 16.563
202012 5.071 260.474 6.429
202103 14.558 264.877 18.149
202106 9.551 271.696 11.608
202109 20.626 274.310 24.829
202112 7.476 278.802 8.855
202203 17.748 287.504 20.384
202206 14.609 296.311 16.280
202209 24.099 296.808 26.811
202212 22.740 296.797 25.300
202303 -10.588 301.836 -11.583
202306 22.731 305.109 24.601
202309 10.541 307.789 11.309
202312 10.904 306.746 11.738
202403 15.285 312.332 16.160
202406 -52.994 314.175 -55.699
202409 29.478 315.301 30.872
202412 36.687 315.605 38.385
202503 27.137 319.799 28.021
202506 2.432 322.561 2.490
202509 47.324 324.800 48.113
202512 45.891 324.054 46.763
202603 30.877 330.213 30.877

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN41.13 mean?
Incyte (MEX:INCY) has a Cyclically Adjusted FCF per Share of MXN41.13 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's Cyclically Adjusted FCF per Share too high?
Incyte's current Cyclically Adjusted FCF per Share is MXN41.13. Overall, Incyte has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted FCF per Share compare to INSM and BNTX?
Incyte's Cyclically Adjusted FCF per Share of MXN41.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current Cyclically Adjusted FCF per Share is MXN41.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,797.83, compared to a current price of MXN2,067.00 — trading 15% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN41.13. Incyte's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Cyclically Adjusted FCF per Share is MXN41.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,067.00 is trading 15% above its estimated GF Value™ of MXN1,797.83. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Cyclically Adjusted FCF per Share: MXN41.13
  • GF Value™: MXN1,797.83 vs. price of MXN2,067.00 (15% above fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
83GF Score

Get the complete analysis for MEX:INCY

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,067.00
Price
MXN1,797.83
GF Value